Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DKK1 | O94907 | 3/20 | 0.57 |
| ▸ | CKS1B | P61024 | 7/20 | 0.45 |
| ▸ | SKP1 | P63208 | 7/20 | 0.45 |
| ▸ | SKP2 | Q13309 | 7/20 | 0.45 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.44 |
| ▸ | VCP | P55072 | 1/20 | 0.43 |
| ▸ | ACACB | O00763 | 1/20 | 0.42 |
| ▸ | ACACA | Q13085 | 1/20 | 0.42 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.41 |
| ▸ | SORD | Q00796 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1729056 | 0.85 | DKK1 (0.66) | DKK1CKS1BSKP1SKP2HCAR2 | |
| SCHEMBL240063 | 0.84 | CKS1B (0.48) | CKS1BSKP1SKP2ACACBACACA | |
| SCHEMBL3265549 | 0.82 | CHRM4 (0.50) | DKK1ACACB | |
| SCHEMBL3268917 | 0.81 | CKS1B (0.47) | CKS1BSKP1SKP2ACACBACACA | |
| SCHEMBL3265598 | 0.80 | CKS1B (0.46) | CKS1BSKP1SKP2 | |
| SCHEMBL3265694 | 0.80 | P2RX7 (0.47) | CKS1BSKP1SKP2 | |
| SCHEMBL3265642 | 0.78 | CKS1B (0.51) | CKS1BSKP1SKP2 | |
| SCHEMBL3650257 | 0.77 | DKK1 (0.82) | DKK1CKS1BSKP1SKP2HCAR2 | |
| SCHEMBL2757435 | 0.77 | DPP4 (0.44) | DKK1CKS1BSKP1SKP2HCAR2 | |
| SCHEMBL3266878 | 0.76 | CKS1B (0.45) | DKK1CKS1BSKP1SKP2VCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120004207-A1 | THERAPEUTIC USES OF DERIVATIVES OF PIPERIDINYL-AND PIPERIDINYL-ALKYL CARBAMATES | SANOFI-AVENTIS (FR) | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004207-A1 | THERAPEUTIC USES OF DERIVATIVES OF PIPERIDINYL-AND PIPERIDINYL-ALKYL CARBAMATES | CLCN2, CLIC1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | DKK1 4744/4885CKS1B 1534/4885SKP1 4286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.